Nimedar is a non-steroidal anti-inflammatory agent of the methanesulfonanilide group that has anti-inflammatory, analgesic and antipyretic properties. Nimedar's therapeutic effect is based on its interaction with the arachidonic acid cascade and reducing prostaglandin biosynthesis by cyclooxygenase inhibition.
Acute pain, primary dysmenorrhea.
Nimesulide should only be used as a second-line drug. The decision to prescribe nimesulide should be made on the basis of an assessment of all patient-specific risks.
In order to minimise the possible undesirable adverse effects, the lowest effective dose should be administered for the shortest possible time. Nimedar should be taken after meals.
The maximum duration of Nimedar treatment course is 15 days.
Adults. 100 mg of nimesulide (1 single-dose packet) twice per day after meals.
Elderly patients. No dose adjustment is required.
Children from the age of 12. No dose adjustment is required.
Patients with impaired renal function. For patients with mild or moderate renal impairment (creatinine clearance of 30–80 ml/min), no dose adjustment is required, while severe renal impairment (creatinine clearance <30 ml/h) is a contraindication for Nimedar use.
Pour the packet contents into a glass, dissolve in water and take orally.
Nimedar is contraindicated for children under 12 years of age.